HEIDELBERG PHARMA AG O.N. overview

EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma to host R&D Webinar following novel data presented at AACR 05.04.2024 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to host R&D Webinar following novel data presented at AACR Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to...

EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 27.03.2024 / 09:01 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative...

EQS-News: Heidelberg Pharma AG / Key word(s): Annual Results Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 25.03.2024 / 07:10 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to...

EQS-News: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty 19.03.2024 / 09:47 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty...

EQS-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study 18.03.2024 / 07:25 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study Data from HDP-101 dose escalation shows first objective responses and...

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 06.03.2024 / 07:46 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE:...

EQS-News: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million 04.03.2024 / 11:19 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent...